Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.

• Clotilde Le Tiec, Aurélie Barrail, Cécile Goujard, A -M. Taburet
• Clinical pharmacokinetics
• 2005

The efficacy of HIV-1 protease inhibitors (PIs) as part of highly active antiretroviral therapy is now well established and has provided benefits to many patients with HIV infection. Atazanavir is a… (More)

Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

• Caroline Bazzoli, Vincent Jullien, Clotilde Le Tiec, Elisabeth Rey, France Mentré, A -M. Taburet
• Clinical pharmacokinetics
• 2010

In patients infected by HIV, the efficacy of highly active antiretroviral (ARV) therapy through the blockade of different steps of the retrovirus life cycle is now well established. As HIV is a… (More)

Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda

• Laurence Ahoua, Gunar Guenther, +7 authors Mar Pujades-Rodriguez
• BMC infectious diseases
• 2009

BACKGROUND Little is known about immunovirological treatment outcomes and adherence in HIV/AIDS patients on antiretroviral therapy (ART) treated using a simplified management approach in rural areas… (More)

Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.

• Monidarin Chou, Julie Bertrand, +8 authors A -M. Taburet
• Antimicrobial agents and chemotherapy
• 2010

The aims of this ANRS12154 open-label, single-center, multiple-dose pharmacokinetic study were to characterize nevirapine pharmacokinetics in a Cambodian population of HIV-infected patients and to… (More)

Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.

• A. M. Taburet, Gilles Raguin, +7 authors P O Girard
• Clinical pharmacology and therapeutics
• 2004

OBJECTIVE This pharmacokinetic study was designed to characterize interactions between amprenavir and the lopinavir-ritonavir combination in patients infected with human immunodeficiency virus in… (More)

Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.

• Gilles Raguin, Geneviève Chêne, +5 authors P O Girard
• Antiviral therapy
• 2004

OBJECTIVES To compare the antiviral efficacy of a salvage therapy combining lopinavir and amprenavir with 200 mg/d or 400 mg/d ritonavir, together with nucleoside reverse transcriptase inhibitors,… (More)

Simplified Assessment of Antiretroviral Adherence and Prediction of Virological Efficacy in HIV-Infected Patients in Cambodia

• Olivier Ségéral, Yoann Madec, +8 authors A Fontanet
• AIDS research and treatment
• 2010

Background. Adherence to antiviral therapy is important for HIV-infected people living in low- and middle-income countries, because of poor access to alternative regimens. Methods. We conducted a… (More)

Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted…

• Aurélie Barrail-Tran, Laurence Morand-Joubert, +7 authors A -M. Taburet
• Antimicrobial agents and chemotherapy
• 2008

The inhibitory quotient (IQ) of human immunodeficiency virus (HIV) protease inhibitors (PIs), which is the ratio of drug concentration to viral susceptibility, is considered to be predictive of the… (More)

Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results.

• Gilles Raguin, Gwendoline Poizat, +5 authors P O Girard
• AIDS
• 2007

We report the results of the extended follow-up at one year of a randomized trial evaluating the virological efficacy of a salvage therapy combining lopinavir and amprenavir with either 200 or 400… (More)

Short-term DHEA administration in recreational athletes: impact on food intake, segmental body composition and adipokines.

• Nicolas Gravisse, Nancy Vibarel-Rebot, +6 authors Katia Collomp
• The Journal of sports medicine and physical…
• 2018

BACKGROUND DHEA administration is potentially therapeutic because it has been shown to decrease fat mass and adipokines and improve eating and mood disturbances. However, its impact on these… (More)

• ‹
• 1
• 2
• ›